Durable Reductions in HbA1c, Body Weight Seen With Semaglutide
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 4, 2023 -- Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.
Cheli Melzer-Cohen, from Maccabi Health Services in Tel Aviv, Israel, and colleagues examined the effect of subcutaneous semaglutide on HbA1c and weight reduction in a large cohort of adult patients treated for up to three years. Data were included for 23,442 patients (mean age, 62.2 years; mean weight, 94.1 kg; mean body mass index, 33.7 kg/m2; mean HbA1c, 7.6 percent).
The researchers found that among 75 percent of patients, the proportion of days covered (PDC) within the first six months was more than 60 percent. In the intent-to-treat analysis, there were significant reductions in HbA1c (by 0.77 percent to a mean of 6.82 percent) and in body weight (by 4.7 kg to a mean of 89.7 kg). The decreases in HbA1c and weight were more pronounced for glucagon-like peptide-1 receptor agonist (GLP-1-RA)-naive patients than those who had previously received GLP-1-RA (HbA1c, −0.87 versus −0.54 percent; weight, −5.51 versus −3.01 kg). Patients with PDC ≥60 versus <60 percent had greater reductions in both HbA1c and weight. In the intent-to-treat analysis, reductions in both HbA1c and weight were maintained over three years. In the as-treated analysis, the durable pattern of reduction was more evident.
"In this large real-world study, we were able to show durable reductions in HbA1c and body weight with emphasis on drug adherence," coauthor Avraham Karasik, M.D., also from Maccabi Health Services, said in a statement. "Data are in line with results in randomized controlled trials and show the long-term stable benefit of once-weekly semaglutide."
The study was funded by Novo Nordisk, the manufacturer of semaglutide.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...
Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income
FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...
Maternal Serum Alpha-Fetoprotein Levels Higher in Black Than White Women
FRIDAY, May 31, 2024 -- Maternal serum alpha-fetoprotein (AFP) levels are higher in Black than White pregnant women, supporting the use of accounting for these differences in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.